Molecular Risk Assessment in Planning Treatment for Patients With Non-Hodgkin's Lymphoma
Completed · Phase 2
Conditions studied: Lymphoma
In brief
RATIONALE: Analyzing genes that are present in cancer cells may be useful as a method for predicting the response of non-Hodgkin's lymphoma to cancer treatment. Imaging procedures such as positron emission tomography (PET) scans may improve the ability to measure how well cancer has responded to treatment. PURPOSE: This phase II trial is studying molecular risk assessment to see how well it works in predicting response to therapy in patients who are receiving treatment for non-Hodgkin's lymphoma.
Key facts
- Study ID
- NCT00055640
- Run by
- Case Comprehensive Cancer Center
- People needed
- 9
- Starts
- 2002-10-01
- Expected to finish
- 2006-03-01
- Last updated by the study team
- 2010-06-10
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center — Cleveland, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.